GLP-1 Agonist
    Research Compound

    Retatrutide (GGG)

    Triple-Action Metabolic Breakthrough

    A novel triple agonist targeting GLP-1, GIP, and glucagon receptors, showing unprecedented weight loss of up to 24% in clinical trials—the most effective obesity treatment ever studied.

    Record-breaking weight lossEnhanced fat oxidationMetabolic rate preservationBlood sugar optimizationLiver fat reduction

    About Retatrutide (GGG)

    Retatrutide (LY3437943) is a groundbreaking investigational triple hormone receptor agonist developed by Eli Lilly. Unlike semaglutide (single GLP-1) or tirzepatide (dual GIP/GLP-1), retatrutide activates three pathways: GLP-1, GIP, and glucagon receptors. This triple mechanism has produced the most dramatic weight loss results ever seen in obesity trials—participants lost up to 24.2% of body weight over 48 weeks. The glucagon component uniquely increases energy expenditure and promotes liver fat reduction, potentially offering benefits beyond what dual agonists can achieve. Retatrutide is currently in Phase 3 clinical trials and represents the next frontier in metabolic medicine.

    Mechanism of Action

    Retatrutide's triple mechanism works synergistically: GLP-1 reduces appetite and slows gastric emptying; GIP enhances insulin sensitivity and may preserve muscle mass; and glucagon increases energy expenditure, promotes fat oxidation, and reduces liver fat. The glucagon component is particularly novel—while glucagon is typically associated with raising blood sugar, at therapeutic doses combined with GLP-1, it creates a metabolic environment that dramatically favors fat burning while maintaining glucose control.

    How Retatrutide (GGG) Works in Your Body:

    • Target Receptors: Retatrutide (GGG) binds to specific receptors that trigger downstream signaling cascades related to its primary benefits.
    • Physiological Response: The body responds by modulating natural processes—whether hormone release, tissue repair, or cellular signaling—without replacing endogenous function.
    • Timeline: Effects typically begin within a few days, with optimal results seen over the recommended protocol duration.

    Dosing Protocol

    Frequency

    Once weekly (injectable)

    Timing

    Same day each week

    Duration

    Ongoing with medical supervision

    Important Notes

    Currently in clinical trials. Titration starts at 0.5mg weekly, escalating to maximum doses of 8-12mg based on tolerability. Expect approval timeline of 2025-2026.

    Clinical Research

    4 studies on Retatrutide (GGG)

    Study #01

    Phase 2 TRIUMPH Trial

    Participants on highest dose (12mg) lost an average of 24.2% body weight at 48 weeks—the largest reduction ever seen in an obesity drug trial.

    Study #02

    Liver Fat Reduction

    Retatrutide reduced liver fat by up to 82% in participants with NAFLD/NASH, suggesting significant hepatoprotective effects beyond weight loss.

    Published in The Lancet
    Study #03

    Metabolic Rate Analysis

    The glucagon component helped maintain resting metabolic rate during weight loss, potentially reducing the metabolic adaptation that typically slows weight loss.

    Study #04

    Dose-Response Relationship

    Clear dose-dependent weight loss observed: 8.7% at 1mg, 17.5% at 4mg, and 24.2% at 12mg weekly doses.

    Published in Obesity

    Potential Side Effects

    • Nausea (common, dose-dependent)
    • Diarrhea
    • Vomiting
    • Decreased appetite
    • Constipation
    • Injection site reactions

    Stacks Well With

    Combining peptides can create synergistic effects. Learn about optimal timing, dosing, and protocols.

    Learn More About Retatrutide (GGG)

    Explore our research library and educational resources to understand how Retatrutide (GGG) can support your health goals.